Brown recluse spider (Loxosceles reclusa) venom induces severe dermonecrotic lesions. The mechanism for this is unknown but presents an interesting paradox: necrosis is completely dependent on the victim's neutrophils, yet neutrophils are not activated by the venom. We show Loxosceles venom is a potent, but disjointed, endothelial cell agonist. It weakly induced E-selectin expression, but not intercellular adhesion molecule-i or IL-6 expression, yet significantly stimulated release of IL-8 and large amounts of GM-CSF by 4 h. In contrast, TNF strongly induced all of these, except for GM-CSF. PMN bound to E-selectin on venom-activated endothelial cells, apparently via counterreceptors different from those that bind E-selectin on TNFa-activated monolayers. Notably, PMN bound venom-activated monolayers only at intercellular junctions, did not polarize, and completely failed to migrate beneath the monolayer. Despite this, bound PMN demonstrated increased intracellular Ca2" levels and secreted primary and secondary granule markers. The latter event was suppressed by sulfones used to treat envenomation. We have defined a new endothelial cell agonist, Loxosceles venom, that differentially stimulates the inflammatory response of endothelial cells. This, in turn, leads to a dysregulated PMN response where adhesion and degranulation are completely dissociated from shape change and transmigration. (J. Clin. Invest. 1994.94:631-642.)
Introduction
Envenomation by the brown recluse spider (Loxosceles reclusa), its desert counterpart (Loxosceles deserta) (1, 2) , or the South American Loxosceles Loeta (1) can result in an impressive dermonecrotic lesion. This progresses from an acute local inflammatory reaction to a black eschar, where sloughing of the necrotic tissue leaves a draining, well demarcated ulcer (3) . These lesions are remarkable considering that these spiders emit only a few tenths of a microliter of venom (4) . The mechanism by which the venom causes necrotic lesions is currently un-known. The PMN (neutrophil) might be expected to be the central target of the venom because depletion of PMN with a single dose of nitrogen mustard delays hemorrhage, edema, and necrosis until the pool of circulating neutrophils is reestablished (5) . This key observation shows that PMN are likely the proximal cause of the tissue destruction associated with the intense inflammatory reaction after envenomation. However, human neutrophils are not themselves activated by the venom ex vivo and, in fact, are actually inhibited by it (6, 7) . This apparent paradox may be resolved by the observation (8) that the first ultrastructural change after envenomation is selective damage to vascular endothelium, while at the level of light microscopy it is adhesion of neutrophils to the capillary wall (9) . This suggests that an essential component of this inflammatory reaction may be activation of vascular endothelium, with subsequent sequestration and activation of passing neutrophils by the perturbed endothelial cells.
The initial step in leukocyte emigration from the blood stream is their interaction with the endothelium. This may occur either by directly activating neutrophils, which functionally upregulates their CD11/CD18 adhesive glycoprotein complex, or by activating endothelial cells to express neutrophil tethering and activating molecules (10) . Adhesion by the activated CD1 1/ CD18 integrins is sensitive to the shear (11) of flowing blood and in the absence of stasis is not likely to be the initial event in leukocyte interaction with the vascular wall. In contrast, endothelial cell-dependent adhesion, by virtue of the adhesion molecules presented by activated endothelial cells, is resistant to this. There is a general paradigm by which activated endothelial cells bind neutrophils: two inflammatory processes use different molecules to accomplish similar functions (10) . Agonists like thrombin and histamine within minutes induce the translocation of P-selectin from intracellular granules, Weibel-Palade bodies, to the apical endothelial cell surface. Surface P-selectin acts to tether neutrophils to the endothelial cells by binding to a sialylated counterreceptor on neutrophils. Simultaneously, endothelial cells synthesize platelet-activating factor and translocate it to their plasma membrane, where it can activate the tethered neutrophils through a specific receptor. This juxtacrine stimulation ensures that only adherent neutrophils are stimulated to extravasate. Similarly, endothelial cells exposed to TNFa, IL-1, or endotoxin begin to synthesize and then express a related tethering molecule, E-selectin (10, 12) . This process occurs over a period of hours as neither E-selectin nor its mRNA is detectable in unactivated endothelial cells. Tethered PMN are activated by cytokine-induced endothelial cells and, although the nature of the neutrophil stimulatory molecule(s) in this setting is not completely defined, cytokine-activated endothelial cells also begin to synthesize and release the PMN agonist IL-8.
Here we tested the hypotheses that Loxosceles venom is an endothelial cell agonist and that these activated endothelial cells in turn activate PMN. We exposed primary cultures of human umbilical vein endothelial cells to minute amounts of Loxosceles venom and found that by 4 h treated monolayers bound and activated human neutrophils. However, the venom differentially induced endothelial cell inflammatory events. We found a weak, but functional, expression of E-selectin compared with TNFa-activated monolayers, a complete lack of IL-6 induction, coupled with a strong IL-8 and GM-CSF response. The synthesis and release of GM-CSF were particularly noteworthy as this cytokine is only produced at later times after TNFa activation. However, more striking was the PMN response to this dysregulated endothelial cell activation. PMN adhered only to the junctions of venom-activated endothelial cells, and they did not alter their morphology to a polarized form nor did they migrate beneath the monolayer. Despite this lack of motile responses, adherent PMN released contents from both primary and secondary granules. Therefore, we have defined a new endothelial cell agonist, but find that it differentially induces inflammatory responses of endothelial cells: it dissects events leading to PMN shape change and chemotaxis from those that result in degranulation. This dysregulated inflammatory response may account for the tissue destruction associated with envenomation by Loxosceles spiders.
Methods
Materials. Venom, collected from the fangs of Loxosceles deserta by electrical stimulation of the spiders (to prevent contamination with gastric contents), was obtained from Spider Pharm (Feasterville, PA) [(215) 355-8295]. Venom was stored as small aliquots at -80'C; it was thawed, diluted 100-fold with HBSS containing 0.5% human serum albumin (HBSS/A)', and centrifuged in a microfuge to remove precipitated material. A fresh lot was prepared weekly as thawed venom loses activity over a period of several days and is inactivated by a single round of freeze/thaw after this dilution. Cells, manipulations, and imaging. Human umbilical vein endothelial cells (HUVEC) were cultured in 24-mm multiwell plates (Costar Corp., Cambridge, MA) as described (13) . Only monolayers of primary cultures that were tightly confluent were used for these studies. Neutrophils were isolated from human blood and labeled with ...In-oxine as described (13) . Endothelial cells were treated with the stated agonist in HBSS/A for the specified period of time and washed with HBSS, and the percentage of "'In-neutrophils that tightly adhered in 5 min was quantified as described (14) . HL60 cell adhesion and a parallel PMN control were quantitated by counting the number of adherent leukocytes in five random high-power fields. When the effect of antibodies on PMN-endothelial cell interactions was examined, the appropriate cell was preincubated with 10 ,4g/ml of the mAb for 30 min, and the adhesion assay was performed in the presence of this concentration of antibody. This standard concentration of antibody may not have been optimal for all antibodies, but the limiting amount of some antibodies precluded extensive characterization of each. A positive control for antibody effectiveness was included in each experiment. Potential effects mediated by endotoxin were assessed using polymyxin B to sequester it: 10 ,ug of polymyxin B was added to buffer, appropriately diluted venom, or 20 ng/ml endotoxin as a control. The ability of venom to directly promote neutrophil adhesion via CDlI/CD18 functional upregulation was determined by measuring adhesion to a gelatin matrix as described (15) . Protein synthesis was inhibited in endothelial cell monolayers by incubating the monolayers with 5 jug/ml actinomycin D or 5 ptM emetine for 30 min at 370C before addition of the experimental agent. These monolayers, in the continued presence of actinomycin D or emetine, were incubated for 4 h before the effect of the inhibitors on adhesion was determined. The effect of lactose-1-phosphate (16) or chymotrypsin (17) on neutrophil adhesion was determined as described. Adhesion of neutrophils preactivated for 15 min with 1 ptM FMLP or 1 ,uM PMA in calcium-and magnesium-free HBSS was performed by washing the activated neutrophils, resuspending them in HBSS/A, and performing the adhesion assay at 64 rpm (as shear blocks CD18-mediated adhesion) as described (18) . Cells were visualized by capturing the microscopic image with a video camera onto videotape. A framegrabber and NIH Image 1.47 were used to obtain a single image. Confocal microscopy with E-selectin mAb P6E2 was performed as described (19) . PMN were labeled with INDO-1 AM, and Ca2+-enhanced fluorescence was quantitated in a custom microscopic well as described (20, 21) . All adhesion values are reported as the mean and range of duplicate values and are representative of at least two experiments.
Analytical assays. Degranulation of PMN adhering to endothelial cell monolayers was measured by release of lactoferrin and elastase during a 2-h coincubation: these proteins were assayed by sandwich ELISA as described (22) . GM-CSF, IL-6, and IL-8 were quantitated by sandwich ELISA. The capture antibody was mouse anti-human GM-CSF, and the second antibody was polyclonal rabbit anti-human GM-CSF. Horseradish peroxidase-conjugated donkey anti-rabbit IgG Fab' fragments (Amersham Corp., Arlington Heights, IL) were used for detection in this assay, and recombinant human GM-CSF was used to create the standard curve. IL-8 or IL-6 was determined with polyclonal rabbit anti-human antibody; detection used biotinylated rabbit antihuman IL-8 or IL-6 and avidin-conjugated horseradish peroxidase. When the effect of dapsone (or other sulfones) on degranulation was examined, it was present at the stated concentration during the neutrophil-endothelial cell coincubation. FACS® analysis of PMN L-selectin was performed with fluorescein-conjugated Leu-8 (Becton Dickinson, San Jose, CA). E-selectin on the surface of control and activated endothelial cell monolayers was visualized by confocal microscopy with a fluorescent second antibody as described (23) . Surface in PBS and stained with anti-E-selectin (P6E2) or ICAM-1 (18E3D) monoclonal antibody in this buffer. Staining with FITC-conjugated goat anti-mouse (Sigma Immunochemicals), also in 50% horse serum, was followed by fixation in 0.5% formaldehyde. Viability of recovered unfixed cells was examined in parallel using propidium iodide stain; this population was used to gate FITC-labeled cells. Material for Western blots was collected by solubilizing monolayers with boiling sample buffer containing 10% SDS but not /3-mercaptoethanol. Proteins were electrophoretically separated under nonreducting conditions on 7.5% SDS polyacrylamide gels and then transferred to Immobilon (Millipore) membrane. The membrane was blocked with 5% nonfat milk and probed with the anti-E-selectin monoclonal antibody BBA-8 (British Biotechnology). This was developed with horseradish peroxidase-conjugated polyclonal goat anti-mouse in the presence of 100 ,ug/ml nonimmune rabbit IgG. Staining was detected with ECL (Amersham Corp.) and Kodak XAR-5 film according to the manufacturer's instructions. NIH Image 1.47 was used to estimate the density of the scanned bands. Reverse transcription of cDNA from endothelial cell monolayers grown in 0.8-cm wells and PCR (25 cycles) quantitation of E-selectin message, using glyceraldehyde-3-phosphate dehydrogenase as a control, were performed using manufacturer's protocols under quantitative conditions (24) . The forward primer El 11 1F was 5' ACT TCA CCT GTG AGG AAG GCT TC-3', while the reverse primer E1682R was 5' GCA GAG CCA TTG AGC GTC CAT CCT-3' (25).
Results
Loxosceles venom activates endothelial cells. We exposed primary cultures of endothelial cells to varying amounts of Loxosceles venom for 4 h, washed them, and then incubated freshly isolated, unactivated PMN with these monolayers. We found that PMN bound to venom-activated endothelial cells and that adhesion was dependent on the amount of venom used ( Fig. 1 A). The venom was quite potent, as little as 0.01 Ml/ml significantly enhanced endothelial cell-dependent PMN adhesion. This sensitivity of endothelial cells to the venom is consistent with the ability of a few tenths of a microliter of injected venom to elicit an effect in vivo. Although levels of neutrophil adhesion could be attained that were equivalent to those of cytokineactivated monolayers, the limited supply of venom dictated that the majority of our experiments be performed with submaximal amounts (0.1 Al) of venom. We next exposed endothelial cells to the venom for various periods of time, and then examined the ability of unactivated PMN to bind in 5 min to the treated monolayers. We found (Fig. 1 B) that development of the adhesive surface required at least 2 h of exposure to venom, while maximal adhesion normally developed after 6 h of continuous venom exposure. At this time, PMN adhesion nearly equaled that induced by exposure to TNFa. Even though adhesion after 4 h of venom exposure typically was only half that induced by cytokine activation, we used this time in all other experiments to simplify the pattern of adhesion molecules expressed by the cytokine-treated positive controls (18, 26 (Fig. 1 A) . We conclude that in this system the venom is an endothelial cell-specific agonist.
PMN-endothelial cell interaction appears to be selectin mediated. Endothelial cell-dependent adhesion, whether mediated by P-selectin or E-selectin, has several distinguishing characteristics. Our initial approach to defining the relevant adhesion molecule on venom-activated endothelial cells was to determine if the attributes of selectin-mediated adhesion were displayed in this system. We found (Fig. 2 ) PMN adhesion to venomactivated monolayers to be resistant to shear force, a selectin attribute. We also found that adhesion was inhibited by the chelator EDTA ( Fig. 2 ) and that Ca2" or Mg2" partially restored adhesion (not shown). Together, these ions completely overcame the inhibition of adhesion by EDTA. Selectins recognize sialylated carbohydrate ligands on PMN (27) . Accordingly, we observed that pretreatment of the PMN with sialidase blocked adhesion to monolayers exposed to Loxosceles venom ( Fig. 2) , as well as to TNFa-treated monolayers, the positive control. The counterligand on PMN that binds to E-selectin is lost by either activation of the PMN before the adhesion assay (28) or by pretreatment with low concentrations of chymotrypsin (17, 29) . We found (Fig. 2 ) that both of these treatments blocked PMN adhesion to venom-and TNFa-treated monolayers. These data indicate that PMN adhesion to Loxosceles-exposed endothelial cells is consistent with a selectin being the tethering molecule. To strengthen this inference, we determined if other leukocyte or endothelial cell adhesion molecules had a role in venom-induced adhesion. We found that blocking anti-,61 ( proadhesive surface from that induced by TNFa. For instance, E-selectin recognizes a sialylated ligand on PMN and undifferentiated HL60 cells, and both of these cells adhere to cytokineactivated endothelial cells (25) . We found that, while undifferentiated HL60 cells would bind to TNFa-activated endothelial cells, they would not adhere to venom-activated endothelial cells (Fig. 5 A) . The simplest explanation for this is that these two cells express different ligands for E-selectin and that HL60 cells do not recognize E-selectin expressed by venom-treated endothelial cells. This conclusion is strengthened by the results in Fig. 5 (Fig. 6 ). This unusual pattern was caused by adhesion of the PMN almost exclusively over endothelial cell junctions (this was apparent when the focal plane was altered to visualize endothelial cells rather than the PMN bound to their surface). In contrast, PMN adhered diffusely over TNFa-activated monolayers and then rapidly migrated to and through intracellular junctions. A second unusual characteristic of PMN adherent to venom-activated monolayers was that PMN bound to endothelial cell junctions did not change shape from spherical to the spread, polarized morphology that was apparent on cytokine-activated monolayers. Furthermore, these spherical PMN did not migrate below the monolayer and remained on the apical aspect of endothelial cell junctions for at least the 2 h during which we followed them. This result was quite different from the migration within minutes of PMN below cytokine-stimulated monolayers.
Venom-activated endothelial cells differentially express neutrophil agonists. Endothelial cell-dependent PMN adhesion results from both expression of a tethering molecule and a signaling molecule to induce functional responses from the bound PMN (10, 30) . We considered the possibility that the lack of altered PMN morphology and migration below venom-treated endothelial cell monolayers was due to the expression of a tethering molecule in the absence of an appropriate neutrophil agonist. This seemed possible given the weak expression of Eselectin described above. Accordingly, we determined if venomactivated endothelial cells synthesized and released IL-8, an early response gene product that is a potent mediator of neutrophil activation and extravasation (35-37). We collected supernatants of monolayers treated with TNFa or Loxosceles venom and quantified IL-8 by ELISA. We found that, in contrast to the weak induction of E-selectin, venom-exposed monolayers were significant producers of this cytokine: IL-8 production was stimulated 10-fold by the venom, compared with a 22-fold induction in response to TNFa (Fig. 7) . Moreover, we found a second cytokine, GM-CSF, was induced by venom exposure, and unexpectedly that its accumulation by 4 h was far in excess of that expressed by TNFa-exposed monolayers: Loxosceles venom induced a 6.4-fold increase in GM-CSF release compared with a 30% increase induced by TNFa. This result was unexpected as stimulation of GM-CSF release is slow; elaboration in response to TNFa is detectable only by 8 h of exposure (38) . Elaboration of this cytokine would also have functional consequences for adherent PMN since it is a direct PMN agonist (39) (40) (41) as well as a potent priming agent (42 Release of lytic enzymes from PMN, particularly those localized within the vascular lumen, might have adverse consequences after envenomation. Dapsone (a sulfone that dampens leukocyte responses) has been used as a therapy after Loxosceles envenomation (44) and is one of the few maneuvers aside from surgical excision of the lesion that may be successful. Therefore, celes venom/ml. After the incubation, the buffer was removed, the monolayers were washed, and INDO-1-labeled PMN were added at the time marked by the arrow. Increases in the ratio of fluorescence at 410 vs 480 during excitation at 380 nm was measured as described in Methods. These recordings are representative of three other experiments performed under the same conditions. we examined the effect of this compound on degranulation after adhesion to venom-activated monolayers. We found no effect of dapsone, or other sulfones, on PMN adhesion to venomactivated endothelial cells (not shown). However, dapsone, over a range previously shown to reduce PMN-dependent endothelial cell cytotoxicity (45) , reduced lactoferrin release by 20 and 80% at 10 and 100 Mug/ml, respectively. These observations suggest a molecular mechanism by which dapsone might mitigate the response to Loxosceles envenomation.
Discussion
Envenomation by the brown recluse spider can generate severe dermonecrotic lesions and may extend to hemorrhagic involve- ment of liver and small intestines (4, 46) . The size of the lesions can be large, even though these spiders only emit a tenth to a half a microliter of venom upon stimulation (4). The mechanism by which Loxosceles venom induces necrotic lesions has remained elusive. It is clear that PMN depletion completely protects against the pathologic processes induced by the venom (5), demonstrating that the proximal event is inappropriate PMN activation. Paradoxically, PMN are not directly activated by the venom at relevant doses: the initiating event must lie elsewhere. Morphologic examination of tissues shows that leukocyte adherence to the capillary wall, the first observable change, occurs an hour after envenomation (Geren, C. R., unpublished observation). By 3 h, endothelial cell damage becomes apparent at the ultrastructural level (8) . These events suggest that the primary action of the toxin might be on the blood vessels (47) . We have confirmed this possibility: the venom of Loxosceles reclusa activates endothelial cells. One measure of this activation is that venom-activated endothelial cells bind PMN and then provoke these cells to release the lytic contents of their granules. Unusually, these bound PMN fail to become polarized, a requirement for effective directed migration, and do not emigrate through the monolayer. This endothelial cell-dependent neutrophil stasis coupled with stimulated degranulation at the intimal surface may account for the untowards effects of envenomation. PMN normally do not interact with the vascular wall but, in response to injury or a variety of endothelial cell-or PMNspecific agonists, they begin to roll along the vessel wall and some eventually become tightly bound. These then may exit the vascular system after their morphologic transition from round cells to migrating, polarized cells. Adhesion of PMN in response to direct agonists results from the functional upregulation of their CD 1I/CD 18 integrins, which then bind to target molecules on endothelial cells. Adhesive interactions exclusively by this mechanism are likely to occur only where shear stress from flowing blood is reduced because the strength of this interaction, at least initially, is weak (1 1). In contrast, activation of the endothelium results in the expression of molecules that can mediate shear-resistant interactions. In response to rapidly acting agonists like thrombin or histamine, endothelial cells translocate P-selectin from intracellular Weibel-Palade bodies to their apical surface where it binds sialic acid-containing glycoproteins on unactivated PMN (27, 48 (25) and they adhere to dishes coated with recombinant E-selectin chimeras (53, 54) . Thus, in the literature and in our hands, HL60 cells adhere to E-selectin. It was therefore unexpected that this promyelocytic cell line would fail to adhere to venom-activated monolayers expressing Eselectin. However, in addition to binding to structures containing the sialylated Lewis x antigen (12), E-selectin recognizes other, undefined, counterreceptors (54, 55) . Particularly relevant to our results is the observation (54, 56) that the density of Eselectin affects ligand binding and selection. Our data show that surface expression of E-selectin after venom exposure is sparse: we find that < 10% of the amount of E-selectin expressed in response to TNFa is expressed after venom treatment. This low level of E-selectin expression may account for the unusual behavior of venom-activated monolayers towards PMN: the low level expression dictates that a different counterreceptor, potentially one that is less abundant but with a greater affinity, is recognized by this E-selectin than when it is more abundant. That a different counterreceptor is used by endothelial cells activated with the two agonists is readily apparent. We found differential sensitivity to lactose-I-phosphate, chymotrypsin pretreatment, and a complete inability to bind HL60 cells. Conversely, our data suggest that E-selectin is present in great excess, at least for the purposes of adhesion, on TNFa-stimulated endothelial cells since the much lower amounts present on venom-treated cells can mediate the same level of neutrophil adhesion. Abundant expression of E-selectin may alter the ligand selection of some vascular endothelial cells and allow multivalent interaction with lower affinity neutrophil counterligands, but once a neutrophil enters an environment with less abundant E-selectin expression its behavior may more closely approximate the adhesive interactions with venom-activated cells than the maximally stimulated expression of cytokine-activated monolayers.
The limited amount of E-selectin on the surface of venomstimulated monolayers was presented in the context of basal levels of ICAM-1 surface expression, and an anti-ICAM-1 monoclonal antibody had no discerable effect on PMN adhesion to venom-treated monolayers. Although ICAM-1 and Eselectin can be independently regulated (57, 58) , here there was little evidence of this. One caveat here is that basal expression of ICAM-1 would cloud our detection of small increases in ICAM-1 expression; however, we found another response that demonstrates that the venom does not completely mimic all of the actions of TNFa. We found that, under conditions where similar levels of PMN adhesion were induced by venom and TNFa, expression of IL-6 was detectable only in supernatants derived from TNFa-treated monolayers. Here, where control monolayers secrete no detectable IL-6, the responses to TNFa and Loxosceles venom are noticeably different. Differential stimulation of endothelial cell function is also apparent when E-selectin expression is compared with elaboration of IL-8. In contrast to its weak effects on expression of this adhesion molecule, we found that elaboration of IL-8 in response to venom was nearly half that induced by TNFa after 4 h of exposure and about 60% of that induced by TNFa by 8 h (not shown). That this ratio was maintained over time shows that this truly represents differential induction rather than just an altered rate of expression. Unexpectedly, we found that venom also caused a large and early induction of GM-CSF release into the overlaying medium. Endothelial cells respond to IL-1 and TNFa with increased synthesis and release of GM-CSF (38, 59, 60) , but production is a prolonged process: TNFa-evoked bioactivity is just detectable at 8 h with increased levels after 24 h (38); our ELISA failed to detect enhanced levels of GM-CSF by 4 h of TNFa stimulation. Our results show that the amount of immunoreactive GM-CSF released by 4-h venom stimulation is equivalent to that released by endothelial cells exposed to IL-1 for 24 h (59): for this response, then, differential induction by these two agonists was a temporal one.
Cytokine induction of E-selectin, ICAM-1, IL-8, and GM-CSF expression is complex and, at least for ICAM-1 (61) and GM-CSF (62), reflects both transcriptional and posttranscriptional regulation. The promoter regions of E-selectin, IL-8, IL-6 (63), and ICAM-1, but not GM-CSF, contain NF-KB recognition elements that are essential for enhanced transcription after cytokine stimulation. Of these, only for IL-8 is the formation of an NF-KB complex necessary and (in conjunction with a constitutive c/EPB transcription factor) sufficient (64) for effective transcription: E-selectin (65-67), ICAM-1 (61, 68) , and IL-6 (69) require additional factors for efficient promoter activity. Additionally, regulation of E-selectin transcription may have an additional layer of complexity in that two different NF-KB heterodimers bind the NF-KB recognition sequence (67). Eselectin expression is also modulated under some conditions by cAMP levels (70), but we found no evidence that increased levels of cAMP accounted for the differential expression of Eselectin between TNFa-and venom-treated monolayers: exposing venom-activated monolayers to 100 ILM Rp cAMP to inhibit cAMP-dependent kinase activity did not increase Eselectin expression of venom-treated monolayers (data not shown). Thus, a parsimonious explanation for our results is that venom leads to the release of NF-KB from its cytoplasmic inhibitory complex and its translocation to the nucleus where this single event induces IL-8 transcription. In support of this, we find by electrophoretic mobility shift assays that Loxosceles venom treatment, like TNFa exposure, results in the intranuclear appearance of KB element binding factors that appropriately shift a KB probe (not shown). The low production of Eselectin, IL-6, and ICAM-1 suggests that other factors essential for efficient transcription of these genes are not produced upon venom exposure. The effect of venom on GM-CSF production is less obvious given the major effect of message stability on its production (60, 62) and that the identified regulatory element is a target for an unknown transcription factor. Independent control of GM-CSF and E-selectin transcription has been shown previously; an antisense oligonucleotide to the GM-CSF regulatory element blocks GM-CSF expression in IL-1-stimulated endothelial cells, but has no effect on E-selectin expression (59) . We anticipate that the availability of an unusual agonist that differentially induces a panel of inflammatory cytokines and adhesive proteins will provide a new and valuable approach to define the intracellular signaling events in activated endothelial cells.
In addition to a differential induction of endothelial cell inflammatory responses, an intriguing difference between PMN interaction with venom-and cytokine-activated endothelial cells is the distribution of adherent PMN. Rather than occurring randomly over the apical surface of activated endothelial cells, PMN adhesion to venom-activated monolayers occurred just over endothelial cell junctions. We found, by video microscopy, that neutrophils contacting the monolayer slide or roll to the edge of an endothelial cell and then jostle one another to form a pattern that, at the microscopic level, appears as beads on a string. This pattern of adhesion probably does not result directly from the exclusive expression of E-selectin at the borders of venom-activated endothelial cells, as examination of unfixed monolayers by confocal microscopy showed that E-selectin was not just localized to cellular junctions (not shown). This suggests that other features of endothelial cell junctions are important in PMN-endothelial interactions. A junctional protein, such as CD31, may be involved in this, but we find (Martinez, M., S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre, unpublished observations) that venom treatment disperses CD31 from its junctional location, giving rise to significant staining of the apical surface. Thus PECAM-1 is no longer correctly localized for such a role, and a direct experiment with the blocking monoclonal antibody hec7 (71) failed to alter the unusual pattern of junctional adhesion (not shown). It is intriguing that hec7 treatment of endothelial cells and PMN generates an unusual junctional adhesion pattern just like that of PMN adhering to venom-treated monolayers (71) .
A second, and the most intriguing, difference in PMN response to venom-treated monolayers is that they did not become polarized, nor did they migrate beneath the monolayer. These PMN were spherical and remained at the apical aspect of endothelial cell junctions for at least the 2 h we extended these experiments. This is in contrast to the transmigration of over half the PMN in 5 min when quiescent PMN were exposed to cytokine-stimulated monolayers. We that blocks IL-8 activity failed to relieve the inhibition of transmigration through venom-treated monolayers (not shown).
Although PMN did not change shape or migrate beneath venom-activated monolayers, these endothelial cells did elaborate PMN agonist(s) capable of eliciting polarization and transmigration. IL-8 is a complete PMN agonist, while GM-CSF, in addition to its colony-forming activity, has potent effects on mature PMN. GM-CSF stimulates CDlI/CD18-dependent PMN adhesion (40, 41) , primes PMN degranulation in response to a second agonist (42) , and stimulates release of secondary and tertiary granule markers from adherent PMN (39, 40) . Thus, venom-activated cells release a potent priming agent/agonist in addition to at least two direct PMN agonists. Correspondingly, we found that as PMN settled onto the monolayer their intracellular Ca2+ levels increased rapidly. Furthermore, we found that PMN adhering to venom-activated monolayers released their granular contents. We found both primary and secondary granule contents were released to the same extent from PMN adhering to venom-or cytokine-stimulated monolayers. Since these PMN had not been pretreated with cytochalasin B to enhance degranulation, it is possible that this level of degranulation could also occur in vivo. We conclude sequestration of PMN at sites of envenomation with inappropriate release of lytic enzymes in the vascular space may account for much of the tissue destruction that accompanies envenomation. Attenuation of degranulation of adherent neutrophils by dapsone may provide a rational basis for its use after envenomation.
We have identified a possible cellular and molecular basis for the PMN-dependent necrosis after envenomation by Loxosceles spiders. Prior work aimed at demonstrating a direct effect on PMN, or blood components, has not yielded a mechanism to account for the paradoxical requirement for the victim's PMN in the dermonecrosis that can follow envenomation. The potent effect of the venom on endothelial cells described here suggests that the inappropriate activation of PMN function by the venom is an indirect one. However, Loxosceles venom potently activates some, but not all, of the mechanisms that should result in the regulated extravasation of circulating PMN. The inappropriate accretion of PMN and their activation in the intravascular space suggest that this venom will be a useful tool to dissect the mechanisms that underlie normal leukocyte-endothelial cell interactions.
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